SCHEMBL4671765

SCHEMBL4671765

O=C(Cc1ccc(CCc2ccccc2)o1)C(=O)c1nc[nH]n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.35
HTR2B P41595 1/20 0.34
HTR3A P46098 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
MMP2 P08253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
HTT P42858 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
QPCT Q16769 1/20 0.33
NR3C2 P08235 1/20 0.33
FFAR1 O14842 1/20 0.33
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33
SGMS1 Q86VZ5 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678966 0.90 PTGER1 (0.35) HDAC1HDAC8POLBTDP1CES2
SCHEMBL4675310 0.84 ALDH1A1 (0.49) SMN1; SMN2ALDH1A1POLBMAPTPKM
SCHEMBL4676111 0.81 ALOX5 (0.37) SMN1; SMN2ALDH1A1MAPTPKMHSD17B10
SCHEMBL4676009 0.81 KLKB1 (0.32) SMN1; SMN2ALDH1A1MAPTTDP1CES1
SCHEMBL4672955 0.80 HCAR2 (0.43) HDAC1SMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4678032 0.80 SORT1 (0.32) HTT
SCHEMBL4672900 0.80 HTT (0.33) SMN1; SMN2ALDH1A1HTTHSD17B10TDP1
SCHEMBL4680139 0.80 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1MAPTPKMHTT
SCHEMBL4676887 0.80 HTT (0.34) SMN1; SMN2ALDH1A1POLBMAPTPKM
SCHEMBL4671810 0.79 HCAR2 (0.42) ALDH1A1POLBMAPTNR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 DAO 661/4885HTR2B 217/4885HTR3A 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.